Donors
Donors
With IFFIm, donors have an immediate impact.
With IFFIm, donors have an immediate impact
IFFIm’s financial base consists of grants from 11 sovereign sponsors. As of June 2024, their combined long-term pledges total approximately US$ 9.7 billion. By signing the grant agreements, countries agree to pay these obligations in a specified schedule of payments.
IFFIm frontloads funding for Gavi's vaccine programmes by issuing vaccine bonds based on the entire amount of long-term donor pledges.
This unique financial mechanism enables donors' pledges to go work immediately, saving more lives, faster.
IFFIm is the only aid-financing entity in history to secure legally binding commitments of up to 23 years from donors. When assessing its lifetime cost to date, IFFIm’s weighted average cost of borrowing is broadly in line with the average of its donors.
IFFIm puts long-term donor pledges to work immediately by making Vaccine Bonds available on the world’s capital markets. This frees funds up immediately to help our partners deliver life-saving vaccines without having to wait for pledged donations to come in incrementally, over time.
As of June 2024, the sponsoring countries have committed to pay the following US$ equivalent amounts:
| Country | US$ equivalent | Currency of pledge |
|---|---|---|
 | US$ 4,230 million over 23 years | GBP 2,591 million |
 | US$ 1,884 million over 20 years | EUR 1,390 million |
 | US$ 1,068 million over 25 years | US$ 27 million & NOK 9,100 million* *Includes additional pledges to support the Coalition for Epidemic Preparedness Innovations (CEPI) through Gavi for the development of COVID-19 vaccine candidates |
 | US$ 821 million over 25 years | EUR 654 million* *Includes a pledge to support the Coalition for Epidemic Preparedness Innovations (CEPI) through Gavi for the development of COVID-19 vaccine candidates.
|
 | US$ 487 million over 22 years | EUR 330 million & US$ 67 million |
 | US$ 427 million over 20 years | EUR 365 million* *Includes a pledge to support the Coalition for Epidemic Preparedness Innovations (CEPI). |
 | US$ 346 million over 20 years | AUD 373.5 million |
 | US$ 325 million over 25 years | SEK 2,776 million |
 | US$ 20 million over 20 years | US$ 20 million |
 | US$ 20 million over 20 years | US$ 20 million |
 | US$ 92 million over 8 years | CAD 125 million |
| TOTAL | US$ 9,720 million (approximately) |
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.